Hepatocellular carcinoma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age>= 18 years, regardless of gender; 2. Evidence of liver cirrhosis confirmed by imaging, pathology, or liver stiffness measurement; 3. At least two imaging modalities, such as dynamic contrast-enhanced MRI or dynamic contrast-enhanced CT, showing typical features of hepatocellular carcinoma, combined with clinical diagnosis of primary liver cancer based on medical history and serological tests; 4. Availability of data on HBV-related indicators; 5. Liver function classified as Child-Pugh class A or B; 6. ECOG performance status score of 0-2.
Exclusion criteria
Exclusion criteria: 1. Presence of secondary malignant tumors in the liver; 2. Positive markers for other viral infections, including hepatitis A virus IgM antibodies, hepatitis C virus antibodies, hepatitis D virus IgG antibodies, hepatitis E virus IgM antibodies, or HIV antibodies; 3. Hematologic disorders or other serious conditions that significantly affect coagulation function; 4. Lack of HBV DNA testing and imaging evaluation data at the time of initial HCC treatment and during treatment; 5. Liver function classified as Child-Pugh class C; 6. ECOG performance status score of >= 3; 7. Pregnant women or female participants who do not use contraception; 8. Presence of severe cardiovascular, cerebrovascular, or other systemic diseases that are unstable or uncontrolled; 9. History of substance abuse or any medical, psychological, or social conditions that may affect the study, compromise participant compliance, or endanger participant safety; 10. Determination by the investigator that the participant is unsuitable for this study based on comprehensive judgment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hepatitis B virus load; | — |
Secondary
| Measure | Time frame |
|---|---|
| Imaging indicators; | — |
Countries
China
Contacts
The Fifth Medical Center of the PLA General Hospital